Item 7.01 Regulation FD Disclosure
Neoleukin Therapeutics, Inc. (the "Company") has prepared investor presentation
materials with information about the Company, which it intends to use as part of
investor presentations. A copy of the investor presentation materials to be used
by management for presentations is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
The information in this current report on Form 8-K and in Exhibit 99.1 attached
hereto is being furnished, but shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"),
and is not incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.
Item 8.01 Other Items
The Company announced the following updates to its clinical and preclinical
programs:
•The Company expects interim data on its Phase 1 clinical trial of NL-201 in
patients with solid tumors in 2022, and to initiate a Phase 1 clinical trial of
NL-201 in patients with hematologic malignancies.
•The Company currently has three preclinical programs in the discovery phase:
(1) Neo-202, which is a next generation IL-2/15 agonist; (2) Neo-5171, which is
an IL-2/15 antagonist being developed for the treatment of autoimmune and
inflammatory conditions, and (3) Neo-TRA, which is a T-reg agonist being
developed for the treatment of autoimmune and inflammatory conditions.
•The Company expects to begin its evaluation of NL-201 and KEYTRUDA
(pembrolizumab) in a Phase 1 clinical trial.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits

Number      Description
99.1          Presentation of Neoleukin Therapeutics, Inc. dated January 2022
104         Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses